Novo Nordisk A/S
XMUN:NOVA

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
XMUN:NOVA
Watchlist
Price: 51.4 EUR 0.59%
Market Cap: 174B EUR

Gross Margin

82%
Current
Declining
by 2.2%
vs 3-y average of 84.2%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
82%
=
Gross Profit
kr258.9B
/
Revenue
kr315.6B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
82%
=
Gross Profit
€258.9B
/
Revenue
kr315.6B

Peer Comparison

Country Company Market Cap Gross
Margin
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Merck & Co Inc
NYSE:MRK
275.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.2B USD
Loading...
DE
Bayer AG
XETRA:BAYN
41.9B EUR
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
522.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
207.6B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.4B CHF
Loading...
No Stocks Found

Market Distribution

Higher than 85% of companies in Denmark
Percentile
85th
Based on 447 companies
85th percentile
82%
Low
-2 199.8% — 26.7%
Typical Range
26.7% — 65.9%
High
65.9% — 1 637.7%
Distribution Statistics
Denmark
Min -2 199.8%
30th Percentile 26.7%
Median 45.7%
70th Percentile 65.9%
Max 1 637.7%

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVA Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
82%
=
Gross Profit
kr258.9B
/
Revenue
kr315.6B
What is Novo Nordisk A/S's current Gross Margin?

The current Gross Margin for Novo Nordisk A/S is 82%, which is below its 3-year median of 84.2%.

How has Gross Margin changed over time?

Over the last 3 years, Novo Nordisk A/S’s Gross Margin has decreased from 84.2% to 82%. During this period, it reached a low of 82% on Sep 30, 2025 and a high of 85% on Dec 31, 2024.

Back to Top